December 13, 2019
Shionogi said on December 12 that the UK’s cost-effectiveness watchdogs have recommended the use of Mulpleo (lusutrombopag) through the National Health Service (NHS) for the treatment of certain patients with severe thrombocytopenia. The National Institute for Health and Care Excellence...read more